BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costa RR, Oliveira-da-Silva JA, Reis TAR, Tavares GSV, Mendonça DVC, Freitas CS, Lage DP, Martins VT, Antinarelli LMR, Machado AS, Bandeira RS, Ludolf F, Santos TTO, Brito RCF, Humbert MV, Menezes-Souza D, Duarte MC, Chávez-Fumagalli MA, Roatt BM, Coimbra ES, Coelho EAF. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Med Microbiol Immunol 2021;210:133-47. [PMID: 33870453 DOI: 10.1007/s00430-021-00707-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Mendonça DVC, Tavares GSV, Pereira IAG, Oliveira-da-Silva JA, Ramos FF, Lage DP, Machado AS, Carvalho LM, Reis TAR, Carvalho AMRS, Ottoni FM, Ludolf F, Freitas CS, Martins VT, Chávez-Fumagalli MA, Duarte MC, Humbert MV, Roatt BM, Menezes-Souza D, Alves RJ, Coelho EAF. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study. Exp Parasitol 2021;:108205. [PMID: 34968460 DOI: 10.1016/j.exppara.2021.108205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cohen A, Azas N. Challenges and Tools for In Vitro Leishmania Exploratory Screening in the Drug Development Process: An Updated Review. Pathogens 2021;10:1608. [PMID: 34959563 DOI: 10.3390/pathogens10121608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]